AVEO Oncology Announces Submission of New Drug Application to U.S. FDA for Tivozanib in Patients with Relapsed or Refractory Renal Cell Carcinoma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 31, 2020-- AVEO Oncology (NASDAQ: AVEO) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tivozanib, the Company’s...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news